<DOC>
	<DOC>NCT00457587</DOC>
	<brief_summary>Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.</brief_summary>
	<brief_title>Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>Cushing Syndrome</mesh_term>
	<criteria>patients with histological proven adrenocortical carcinoma healthy persons as control group Life expectancy &gt; 6 months autoimmune diseases severe clinical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>